Oncolytic viruses thrive in cancer cells and can replicate rapidly, destroying the cells and enabling the immune system to attack tumours. This week, we interview Dr Malcolm McColl and Prof Darren Shafren, a dynamic duo in Australian biotechnology and part of the leadership team of ImmVirx, a viral oncolytic company. Prior to creating ImmVirx, they successfully launched the product Cavatak, used in melanoma and other malignancies.

ImmVirx has developed a proprietary bio-selected RNA virus that is showing promising pre-clinical and phase 1 results as monotherapy in hard-to-treat cancers, including colorectal, gastric hepatocellular and ovarian cancers.

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Please find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Oncology for the Inquisitive Mind is recorded with the support of education grants from Pfizer, Gilead Pharmaceuticals and Merck Pharmaceuticals. Our partners have no editorial rights or early previews, and they have access to the episode at the same time you do.

Art courtesy of Taryn Silver

Music courtesy of AlisiaBeats: https://pixabay.com/users/alisiabeats-39461785/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.